Epithelial ovarian cancer: The molecular genetics of epithelial ovarian cancer

Annals of Oncology

Volumn 27, Issue , 2016, Pages i4-i10

  Krzystyniak, J ^a   Ceppi, L ^a   Dizon, D S ^b,c   Birrer, M J ^a,b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; Clinical trials; Genomics; Ovarian cancer

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 18; FP 1039; JANUS KINASE; NINTEDANIB; PROTEIN TYROSINE KINASE INHIBITOR; SELUMETINIB; SMALL INTERFERING RNA; STAT PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; CANCER CELL; CANCER GRADING; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CTNNB1 GENE; CYTOREDUCTIVE SURGERY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENOMICS; HIGH GRADE SEROUD CARCINOMA; HIGH RISK POPULATION; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; LOW GRADE SEROUS CARCINOMA; LOW RISK POPULATION; MOLECULAR GENETICS; OVARY CARCINOMA; OVARY TUMOR; OVERALL SURVIVAL; PERSONALIZED MEDICINE; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; SURGICAL TECHNIQUE; TREATMENT OUTCOME; TREATMENT PLANNING; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; MOLECULAR BIOLOGY; MORTALITY; NEOPLASM; PATHOLOGY; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX;

BIOMARKERS, TUMOR; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MOLECULAR BIOLOGY; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SQUAMOUS INTRAEPITHELIAL LESIONS OF THE CERVIX;

EID: 84966318917     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw083     Document Type: Article

References (46)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65 (1): 5-29.
2. Wright JD, Chen L, Tergas AI et al. Trends in relative survival for ovarian cancer from 1975 to 2011. Obstet Gynecol 2015; 125(6): 1345-1352.
3. Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. Gynecol Oncol 2013; 129(1): 258-264.
4. Farley J, Fuchiuji S, Darcy KM et al. Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimallyresected epithelial ovarian cancers: a Gynecologic Oncology Group Study. Gynecol Oncol 2009; 113(3): 341-347.
5. Mok SC, Bonome T, Vathipadiekal V et al. A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2. Cancer Cell 2009; 16(6): 521-532.
6. Darcy KM, Brady WE, McBroom JW et al. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2008; 111(3): 487-495.
7. Birrer MJ, Johnson ME, Hao K et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol Off J Am Soc Clin Oncol 2007; 25(16): 2281-2287.
8. Spentzos D, Levine DA, Ramoni MF et al. Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol Off J Am Soc Clin Oncol 2004; 22(23): 4700-4710.
9. Bell D, Berchuck A, Birrer M et al. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474(7353): 609-615.
10. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet 2014; 384(9951): 1376-1388.
11. Kuhn E, Kurman RJ, Vang R et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol 2012; 226(3): 421-426.
12. Gershenson DM, Sun CC, Lu KH et al. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol 2006; 108(2): 361-368.
13. Schmeler KM, Sun CC, Bodurka DC et al. Neoadjuvant chemotherapy for lowgrade serous carcinoma of the ovary or peritoneum. Gynecol Oncol 2008; 108(3): 510-514.
14. Gershenson DM, Bodurka DC, Lu KH et al. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. J Clin Oncol 2015; 33(24): 2675-2682.
15. Bodurka DC, Deavers MT, Tian C et al. Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. Cancer 2012; 118(12): 3087-3094.
16. Diaz-Padilla I, Malpica AL, Minig L et al. Ovarian low-grade serous carcinoma: a comprehensive update. Gynecol Oncol 2012; 126(2): 279-285.
17. Gourley C, Farley J, Provencher DM et al. Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas. Int J Gynecol Cancer 2014; 24: S9-S13.
18. Anglesio MS, Arnold JM, George J et al. Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Mol Cancer Res 2008; 6(11): 1678-1690.
19. Bonome T, Lee J-Y, Park D-C et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005; 65 (22): 10602-10612.
20. May T, Virtanen C, Sharma M et al. Low malignant potential tumors with micropapillary features are molecularly similar to low-grade serous carcinoma of the ovary. Gynecol Oncol 2010; 117(1): 9-17.
21. Meinhold-Heerlein I, Bauerschlag D, Hilpert F et al. Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 2005; 24(6): 1053-1065.
22. May T, Shoni M, Crum CP et al. Low-grade and high-grade serous Mullerian carcinoma: review and analysis of publicly available gene expression profiles. Gynecol Oncol 2013; 128(3): 488-492.
23. Farley J, Brady WE, Vathipadiekal V et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, singlearm, phase 2 study. Lancet Oncol 2013; 14(2): 134-140.
24. Grisham RN, Sylvester BE, Won H et al. Extreme outlier analysis identifies occult mitogen-activated protein kinase pathway mutations in patients with low-grade serous ovarian cancer. J Clin Oncol 2015;33(34): 4099-4105.
25. Obata K, Morland SJ, Watson RH et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998; 58(10): 2095-2097.
26. Zorn KK, Bonome T, Gangi L et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res Off J Am Assoc Cancer Res 2005; 11(18): 6422-6430.
27. Rechsteiner M, Zimmermann A-K, Wild PJ et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol 2013; 95(2): 235-241.
28. Anglesio MS, Kommoss S, Tolcher MC et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol 2013; 229(1): 111-120.
29. Jones S, Wang T-L, Shih I-M et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science 2010; 330(6001): 228-231.
30. Wiegand KC, Shah SP, Al-Agha OM et al. ARID1A mutations in endometriosisassociated ovarian carcinomas. N Engl J Med 2010; 363(16): 1532-1543.
31. Anglesio MS, Carey MS, Köbel M et al. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. Gynecol Oncol 2011; 121(2): 407-415.
32. Stany MP, Vathipadiekal V, Ozbun L et al. Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS ONE 2011; 6(7): e21121.
33. Jackson AL, Eisenhauer EL, Herzog TJ. Emerging therapies: angiogenesis inhibitors for ovarian cancer. Expert Opin Emerg Drugs 2015; 20(2): 331-346.
34. Kuo K-T, Mao T-L, Jones S et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol 2009; 174(5): 1597-1601.
35. Campbell IG, Russell SE, Choong DYH et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64(21): 7678-7681.
36. Takano M, Kikuchi Y, Kudoh K et al. Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases. Int J Clin Oncol 2011; 16(5): 605-609.
37. Ganzfried BF, Riester M, Haibe-Kains B et al. curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome. Database 2013; 2013: bat013-bat013.
38. Riester M, Wei W, Waldron L et al. Risk prediction for late-stage ovarian cancer by meta-analysis of 1525 patient samples. J Natl Cancer Inst 2014; 106(5): 1-12.
39. Chang S-J, Bristow RE, Ryu H-S. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Ann Surg Oncol 2012; 19(13): 4059-4067.
40. Wei W, Mok SC, Oliva E et al. FGF18 as a prognostic and therapeutic biomarker in ovarian cancer. J Clin Invest 2013; 123(10): 4435-4448.
41. Thompson MS, Mok SC. Immunopathogenesis of ovarian cancer. Minerva Med 2009; 100(5): 357-370.
42. Robinson-Smith TM, Isaacsohn I, Mercer CA et al. Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice. Cancer Res 2007; 67(12): 5708-5716.
43. Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 2010; 10(2): 116-129.
44. Greulich H, Pollock PM. Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol Med 2011; 17(5): 283-292.
45. Harding TC, Long L, Palencia S et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med 2013; 5(178): 178ra39.
46. Ledermann JA, Hackshaw A, Kaye S et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol Off J Am Soc Clin Oncol 2011; 29(28): 3798-3804.